ALLERGY IMMUNOTHERAPY MARKET ANALYSIS

Allergy Immunotherapy Market, By Treatment Type (Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT) (10-30 MeV, 30 -70 MeV)), By Allergy Type (Allergic Rhinitis, Allergic Asthma, Food Allergy, Venom Allergy, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On January 8, 2024, Inimmune Corporation (Inimmune) and Intrommune Therapeutics, Inc. (Intrommune), clinical-stage companies focused on the development of innovative immunotherapeutics, announced collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy
In May 2021, Glenmark Pharmaceuticals Limited, a pharmaceutical company, launched Ryaltris-AZ Nasal Spray for the treatment of moderate to severe allergic rhinitis, in India
In December 2020, Novartis AG, a pharmaceutical company, announced that it had received an approval from U.S. Food and drug Administration for adults with nasal polyps
In July 2020, Anergis SA, a company developing contiguous overlapping peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs, announced that both companies had entered into a research collaboration. The study will be conducted at the Helmholtz Centre for Infection Research (HZI, Braunschweig, Germany) as part of TRANSVAC2, the European Network of Vaccine Research and Development funded under the European Union's Horizon 2020 Research and Innovation Program